AcrAB Efflux Pump Plays a Role in Decreased Susceptibility to Tigecycline in Morganella morganii

ABSTRACT Transposon mutagenesis of a clinical isolate of Morganella morganii, G1492 (tigecycline MIC of 4 μg/ml), yielded two insertion knockout mutants for which tigecycline MICs were 0.03 μg/ml. Transposon insertions mapped to acrA, which is constitutively overexpressed in G1492, suggesting a role of the AcrAB efflux pump in decreased susceptibility to tigecycline in M. morganii.

[1]  P. Bradford,et al.  Influence of Transcriptional Activator RamA on Expression of Multidrug Efflux Pump AcrAB and Tigecycline Susceptibility in Klebsiella pneumoniae , 2005, Antimicrobial Agents and Chemotherapy.

[2]  S. Amyes,et al.  Role of AcrR and RamA in Fluoroquinolone Resistance in Clinical Klebsiella pneumoniae Isolates from Singapore , 2003, Antimicrobial Agents and Chemotherapy.

[3]  C. Dean,et al.  Efflux-Mediated Resistance to Tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1 , 2003, Antimicrobial Agents and Chemotherapy.

[4]  P. Bradford,et al.  AcrAB Multidrug Efflux Pump Is Associated with Reduced Levels of Susceptibility to Tigecycline (GAR-936) in Proteus mirabilis , 2003, Antimicrobial Agents and Chemotherapy.

[5]  P. Bradford,et al.  In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens , 2002, Antimicrobial Agents and Chemotherapy.

[6]  I. Chopra.  New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  F. Notka,et al.  Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae. , 2002, The Journal of antimicrobial chemotherapy.

[8]  J. Pagés,et al.  mar Operon Involved in Multidrug Resistance of Enterobacter aerogenes , 2002, Antimicrobial Agents and Chemotherapy.

[9]  G. Eliopoulos,et al.  In Vitro Activities of the Glycylcycline GAR-936 against Gram-Positive Bacteria , 2000, Antimicrobial Agents and Chemotherapy.

[10]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[11]  N. Jacobus,et al.  In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936) , 1999, Antimicrobial Agents and Chemotherapy.

[12]  Schweizer Hd.  Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis. , 1993 .

[13]  H. D. Schweizer.  Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis. , 1993, BioTechniques.

[14]  J. Waitz.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically , 1990 .

[15]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[16]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.